Surge in early detection imperatives and companion diagnostics (CDx) integration accelerates global market growth

The global cancer diagnostics market comprises the products, technologies, laboratory services, and clinical procedures used to detect cancer, confirm malignancy, identify tumor characteristics, determine disease progression, and support treatment decisions. It includes diagnostic instruments, reagents and consumables, in vitro diagnostic (IVD) tests, tissue biopsy, molecular diagnostics, immunohistochemistry, medical imaging, and biomarker testing. The market plays an essential role in oncology because accurate and timely diagnosis helps healthcare professionals distinguish between cancer types, assess disease characteristics, and select appropriate treatment strategies. Its growth is driven by the increasing global burden of cancer, an ageing population, greater awareness of early detection, wider screening initiatives, and improvements in diagnostic technologies. Advances in polymerase chain reaction, next-generation sequencing, digital pathology, and artificial intelligence-assisted image analysis are helping laboratories investigate tumor samples with greater analytical detail. The growing adoption of precision medicine is another important driver, as clinicians increasingly rely on genetic alterations and protein biomarkers to identify patients who may benefit from targeted therapies. Liquid biopsy techniques, which analyze tumor-associated material in blood and other body fluids, are also expanding diagnostic research and selected clinical applications, although their use depends on the intended purpose and supporting evidence. Major market activities include research and development, assay development, instrument manufacturing, clinical validation, regulatory approval, laboratory testing, quality control, and collaboration between diagnostic companies, hospitals, research institutions, and pharmaceutical manufacturers. Industry participants such as Roche, Abbott, Thermo Fisher Scientific, Siemens Healthineers, and QIAGEN contribute through diagnostic platforms, reagents, molecular testing technologies, and laboratory solutions. Professional and research organisations, including the American Association for Cancer Research and the American Society of Clinical Oncology, also support scientific advancement through research dissemination, clinical guidance, and professional education.

According to the research report, “Global Cancer Diagnostics Market Overview, 2031” published by Bonafide Research, the Global Cancer Diagnostics Market is expected to cross 105.10 Billion market size by 2031, with 8.45% CAGR by 2026-31. Major companies operating in this field include Roche, Abbott Laboratories, Thermo Fisher Scientific, Siemens Healthineers, Danaher, QIAGEN, Illumina, Hologic, and Agilent Technologies. Market opportunities are expanding through precision oncology, molecular profiling, liquid biopsy, artificial intelligence-assisted pathology, and the development of tests capable of detecting cancer-related biomarkers from blood samples. These innovations can improve diagnostic workflows and provide additional information for treatment selection and disease monitoring. A notable corporate development occurred in March 2026, when Abbott completed its acquisition of Exact Sciences, strengthening its presence in colorectal cancer screening and precision oncology through products including Cologuard and Oncotype DX. The supply chain begins with suppliers of specialised chemicals, antibodies, enzymes, biological materials, plastics, glass, electronic components, and other laboratory inputs. Manufacturers then develop diagnostic reagents, assay kits, instruments, imaging systems, and molecular testing platforms, followed by analytical validation, quality assurance, regulatory review, packaging, and distribution. Products reach hospitals, diagnostic laboratories, cancer centres, and research institutions through direct sales, distributors, reference laboratories, and healthcare procurement networks. Certain reagents require controlled storage and transportation, while instruments depend on installation, maintenance, calibration, and technical support. Laboratory-developed testing services add another pathway in which companies process patient specimens and deliver analytical results directly to healthcare professionals. Growth opportunities also exist in emerging economies, where improved screening infrastructure, local manufacturing, wider laboratory access, and affordable testing solutions could help address unmet diagnostic needs. However, supply chains face challenges involving specialised raw-material availability, manufacturing consistency, regulatory requirements, reimbursement decisions, and unequal access to advanced testing. Companies that strengthen supplier relationships, diversify production, improve turnaround times, and develop clinically validated assays can better serve healthcare providers.

Cancer diagnostic instruments are becoming increasingly important as laboratories move beyond conventional microscopy and manual testing towards automated, data-driven diagnostic processes. These instruments include polymerase chain reaction systems, next-generation sequencing platforms, automated immunohistochemistry equipment, tissue processors, slide scanners, flow cytometers, and specialised laboratory analyzers. Their growing relevance is closely connected to the increasing complexity of cancer diagnosis, which often requires clinicians to combine tissue morphology with molecular and protein biomarker information. For example, molecular testing platforms can identify genetic alterations associated with particular tumors, helping oncologists evaluate whether targeted therapies may be appropriate. Automated immunohistochemistry systems support the consistent processing and staining of tissue samples, while digital pathology scanners convert glass slides into high-resolution digital images that pathologists can review and share remotely. Another important factor is the growing volume of diagnostic information generated by multigene panels and other advanced assays, which requires suitable analytical platforms and supporting software. The World Health Organization and the International Agency for Research on Cancer recognize cancer as a major global public health challenge, reinforcing the need for reliable diagnostic infrastructure across healthcare systems. In the United States, the National Cancer Institute supports research into cancer detection, diagnostic technologies, and precision medicine, helping advance methods that can subsequently be evaluated for clinical use. Instrument manufacturers also compete through improvements in automation, throughput, analytical sensitivity, connectivity, and ease of operation. These developments can reduce manual handling, improve laboratory productivity, and support standardized procedures when systems are properly validated and maintained. Instruments are also needed to implement newer diagnostic approaches, including selected liquid biopsy assays and increasingly sophisticated molecular profiling workflows. Although equipment requires substantial initial investment, its useful life, maintenance requirements, compatibility with consumables, and ability to accommodate new assays influence purchasing decisions.

Biopsy occupies a fundamental place in cancer diagnosis because imaging examinations and clinical symptoms can identify suspicious abnormalities, but a tissue or cellular sample is often required to establish what those abnormalities represent. The National Cancer Institute explains that, in most cases, doctors need a biopsy to be certain that a patient has cancer, with a pathologist examining the collected material and conducting additional tests when necessary. Biopsy procedures vary according to the suspected tumor and its location. Fine-needle aspiration collects cells or fluid, core-needle biopsy obtains a tissue sample, and surgical or endoscopic procedures can provide specimens from areas that are difficult to reach. Image-guided techniques allow clinicians to target suspicious lesions using ultrasound, computed tomography, or other appropriate imaging methods. Once a sample reaches the laboratory, it may undergo fixation, tissue processing, microscopic examination, immunohistochemistry, and molecular testing. These steps help distinguish malignant from benign conditions and identify the cancer's histological subtype. In many cases, biopsy findings also establish whether further biomarker investigations are needed to guide treatment selection. For example, tissue from a lung tumor may be examined for specific genetic alterations that can influence the use of targeted medicines, while breast cancer specimens may be tested for hormone receptors and HER2. The growing importance of personalised oncology therefore increases the diagnostic value of obtaining sufficient, representative specimens. Improvements in needle design, imaging guidance, endoscopic equipment, and specimen-handling procedures can also make biopsy more precise and practical in selected clinical settings.

Lung cancer is an important application within the cancer diagnostics market because the disease presents substantial challenges in early detection, accurate classification, and treatment selection. The International Agency for Research on Cancer reported that lung cancer was the most commonly diagnosed cancer worldwide in 2022, with approximately 2.5 million new cases, and was also the leading cause of cancer death globally. Tobacco smoking remains a major risk factor, while second-hand smoke, air pollution, radon, asbestos, and certain occupational exposures also contribute to disease risk. Many patients do not develop obvious symptoms until the disease has progressed, making timely investigation particularly important. Low-dose computed tomography screening can help detect lung cancer in eligible individuals at high risk, according to applicable screening recommendations, but suspicious findings require further clinical assessment rather than being treated as a definitive diagnosis. Diagnostic pathways may involve chest imaging, bronchoscopy, image-guided needle biopsy, cytological examination, and pathological analysis. After cancer is confirmed, clinicians often need to establish its histological subtype and stage, as these factors influence treatment planning. Molecular testing has become especially important in non-small-cell lung cancer because alterations involving genes such as EGFR, ALK, ROS1, and other actionable targets can determine eligibility for specific targeted therapies. Testing for PD-L1 protein expression can also inform immunotherapy decisions in appropriate clinical settings. These requirements create demand for specialised diagnostic instruments, tissue-processing systems, immunohistochemistry reagents, and molecular assays. Liquid biopsy can provide additional information in selected circumstances, particularly when tumor tissue is insufficient or repeat sampling is difficult, although it does not replace tissue diagnosis in every case. Improvements in bronchoscopy techniques, imaging guidance, laboratory automation, and molecular profiling are helping healthcare providers investigate complex cases more effectively.

Diagnostic centres are gaining importance in cancer diagnostics as healthcare systems increasingly rely on specialised facilities to manage screening, specimen collection, laboratory investigations, and follow-up testing. These centres may operate independently, as part of a hospital network, or through partnerships with diagnostic technology providers and reference laboratories. Their appeal lies in providing dedicated diagnostic services without requiring every patient to enter a hospital for each investigation. Depending on their capabilities, centres can offer mammography, ultrasound, computed tomography, magnetic resonance imaging, biopsy coordination, histopathology, immunohistochemistry, and selected molecular tests. Patients with suspicious findings can be referred for additional investigations, while collected specimens may be sent to specialised laboratories when advanced testing is unavailable on-site. This network-based approach allows diagnostic providers to expand their service coverage without installing every type of instrument at every location. Another factor supporting the channel is the growing importance of early detection and routine screening for eligible populations. As awareness of cancer symptoms and screening recommendations improves, more individuals may seek diagnostic assessment following an abnormal screening result or a clinician's referral. Specialised centres can help manage this demand through appointment-based services, dedicated imaging equipment, and streamlined specimen-handling procedures. Advances in digital pathology and laboratory connectivity also allow diagnostic information to be transferred securely to specialist pathologists for interpretation, supporting collaboration between geographically separated facilities. In addition, the expansion of precision oncology is creating opportunities for diagnostic networks to coordinate molecular profiling and biomarker testing through centralised reference laboratories. Nevertheless, diagnostic centres face operational challenges, including equipment investment, qualified staffing, regulatory compliance, reimbursement limitations, and the need to maintain reliable quality-control procedures. Their ability to provide advanced cancer diagnostics also varies considerably by location and business model.